Increased circulating interleukin‐6 (IL‐6) activity in endotoxin‐challenged mice pretreated with anti‐IL‐6 antibody is due to IL‐6 accumulated in antigen‐antibody complexes
Authors:
- 1 August 1993
- journal article
- research article
- Published by Wiley in European Journal of Immunology
- Vol. 23 (8) , 2026-2029
Abstract
Mice pretreated with monoclonal anti‐interleukin‐6 (IL‐6) antibody and then challenged with lipopolysaccharide (LPS), paradoxically develop higher levels of circulating biological IL‐6 activity, as measured by the hybridoma growth promotion assay, than mice similarly challenged but not pretreated with antibody. Here we provide evidence that this increased biological activity was entirely accounted for by the presence of increased amounts of IL‐6 protein, which could be isolated by immunoaffinity chromatography and subsequently visualized after gel electrophoresis. Chromatography on a protein G matrix and a sandwich ELISA allowed to demonstrate that all IL‐6 present in the serum was in the form of antigen‐antibody complexes. Serum samples of antibody‐treated animals which contained the highest biological activity typically contained near equimolar concentrations of IL‐6 and antibody. In vitro neutralization tests with pure antibody and IL‐6 demonstrated that, with both antibodies tested, more than 1000‐fold molar excess of antibody is needed for neutralization in the hybridoma growth assay. It is concluded that increased biological activity in serum of the anti‐IL‐6 antibody‐treated mice is due to sequestration of the endogenous IL‐6 in the form of antigen‐antibody complexes which, due to the lack of sufficient antibody excess, produce nearly full activity in the hybridoma growth assay.Keywords
This publication has 10 references indexed in Scilit:
- Limited involvement of interleukin‐6 in the pathogenesis of lethal septic shock as revealed by the effect of monoclonal antibodies against interleukin‐6 or its receptor in various murine modelsEuropean Journal of Immunology, 1992
- Protective effect of anti‐interleukin (IL)‐6 antibody against endotoxin, associated with paradoxically increased IL‐6 levelsEuropean Journal of Immunology, 1992
- Role of interleukin 6 (IL-6) in protection from lethal irradiation and in endocrine responses to IL-1 and tumor necrosis factor.Journal of Experimental Medicine, 1992
- Murine anti-interleukin-6 monoclonal antibody therapy for a patient with plasma cell leukemiaBlood, 1991
- Anti‐Interleukin‐6 Antibodies in Normal Human SerumScandinavian Journal of Immunology, 1991
- Essential role for interferon-gamma and interleukin-6 in autoimmune insulin-dependent diabetes in NOD/Wehi mice.Journal of Clinical Investigation, 1991
- Anti-IL-6 monoclonal antibodies protect against lethal Escherichia coli infection and lethal tumor necrosis factor-alpha challenge in mice.The Journal of Immunology, 1990
- Mouse plasmacytoma growth in vivo: enhancement by interleukin 6 (IL-6) and inhibition by antibodies directed against IL-6 or its receptor.Journal of Experimental Medicine, 1990
- Autoantibodies to cytokines - friends or foes?Immunology Today, 1990
- Cloning and Expression of the Human Interleukin-6 (BSF-2/IFNβ 2) ReceptorScience, 1988